Type 2 Diabetes (T2D)
Diabetes
Type 2 Diabetes Introduction
- Nature of the Disease:Type 2 diabetes (T2D) is a metabolic disease caused by insulin resistance and insufficient insulin secretion.
- Pathological Mechanism: The body's cells become less responsive to insulin (insulin resistance), leading the pancreas to produce more insulin to maintain blood glucose levels, eventually causing pancreatic cell failure.
- Typical Onset Age: T2D usually develops in adulthood, but with the rise in obesity, there is a trend of younger onset.
- Primary Impact: In the early stages, it can be managed with diet, exercise, and oral medications. If the condition progresses to pancreatic cell failure, insulin supplementation becomes necessary.
Type 2 Diabetes
It originates from insulin resistance and insufficient insulin secretion, typically developing in adulthood. Current treatment options include diet control, exercise, and medication, with some patients requiring insulin supplementation in later stages.
Pipeline
Product
(Development Code)
(Development Code)
Indication
Preclinical
Phase I
Phase II
Phase III
PS1(PS-001)
Type 2 Diabetes
PS1 alone and in combination can treat TD via immune and endocrine modulation
Excess nutrients
PS1 treatment
Type 2 Diabetes Market Size (2024-2034)
Market Value Projection in USD Billion
Value (Billion USD)
Swipe horizontally to view full chart ➔
90
70
50
30
10
0
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
The global Type 2 Diabetes market size was approximately $37.15 billion in 2024, and is projected to reach around $76.39 billion by 2034, with a compound annual growth rate (CAGR) of 7.47% from 2025 to 2034. An increasing prevalence of Type 2 Diabetes, technological advancements, and growing R&D investments are driving the market's expansion.
Source: Precedence Research
